ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.25 per share for total gross proceeds of $110 million before deducting underwriting di ...

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis’ innovative late-stage pipeline will be highlighted at Eyecelerator and at the American Academy of Ophthalmology (AAO) Annual Meeting. At Eyecelerator, Riad Sherif, MD, Oculis’ Chief Executive Officer, will provide an updat ...

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis’ innovative late-stage pipeline will be highlighted at Eyecelerator and at the American Academy of Ophthalmology (AAO) Annual Meeting. At Eyecelerator, Riad Sherif, MD, Oculis’ Chief Executive Officer, will provide an update ...

Rethinking Ophthalmology Privosegtor FDA update Corporate Update 3 Oculis (Nasdaq / XICE: OCS) Three registrational programs in Neuro-Ophthalmic and Retina indications provide multi- billion-dollar market opportunities October 6th, 2025 Safe Harbor Statements Cautionary note on forward-looking statements These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," ...